


Approved prescription drug products with therapeutic equivalence evaluations.

[Washington, D.C.?] : U.S. Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Bureau of Drugs : 1980-

<http://hdl.handle.net/2027/mdp.39015072933172>

HathiTrust



www.hathitrust.org

Public Domain, Google-digitized

http://www.hathitrust.org/access_use#pd-google

We have determined this work to be in the public domain, meaning that it is not subject to copyright. Users are free to copy, use, and redistribute the work in part or in whole. It is possible that current copyright holders, heirs or the estate of the authors of individual portions of the work, such as illustrations or photographs, assert copyrights over these portions. Depending on the nature of subsequent use that is made, additional rights may need to be obtained independently of anything we can address. The digital images and OCR of this work were produced by Google, Inc. (indicated by a watermark on each page in the PageTurner). Google requests that the images and OCR not be re-hosted, redistributed or used commercially. The images are provided for educational, scholarly, non-commercial purposes.

ME 20.9210:70-1 SUPPL 1

The University
of Michigan
Pharmacy
Library


499-k-3

REFERENCE

SERIAL

Pharm.
RM
300
A653

4th ed.
Suppl. 7



REFERENCE
DO NOT CIRCULATE

**CUMULATIVE
SUPPLEMENT 7
AUG'83 - MAR'84**

**APPROVED
PRESCRIPTION
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

4TH EDITION

THE UNIVERSITY
OF MICHIGAN

JUN 13 1984

MEDICAL
LIBRARY

UNIVERSITY OF MICHIGAN
LIBRARIES

MAY 17 1984

DEPOSITED BY THE
UNITED STATES OF AMERICA

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUGS AND BIOLOGICS

Original from
UNIVERSITY OF MICHIGAN

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN

FOOD AND DRUG ADMINISTRATION
APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
CUMULATIVE SUPPLEMENT

I. PREFACE

This cumulative supplement is one of a series of monthly updates to the Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 4th Edition (the List), to cover interim revisions to the annual publication of the List in its entirety. The List is comprised of several parts and some by their nature, are identified by the term "list". The cumulative supplements routinely provide updates to two of these lists: The Drug Product List and the DESI Addendum.

The List cannot be used effectively without the current cumulative supplement. Users may wish to place an asterisk (*) in the List to the left of the ingredient(s) in the Drug Product List and the product name in the Addendum to indicate that changes to that entry appear in the cumulative supplement. It is also suggested that earlier cumulative supplements be discarded to avoid possible confusion. In this way, only the List and current cumulative supplement need be referenced.

A. DRUG PRODUCT LIST

The Drug Product List cumulative supplements include the changes made since August 1, 1983. Each subsequent cumulative supplement replaces the previous month's cumulative supplement.

Information in this cumulative supplement follows the format of the Drug Product List. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Context information on drug products is provided in each cumulative supplement for completeness to assist in locating the proper place in the Drug Product List for the revision. (Strength(s) which already exist in the publication will not be repeated for context.) A page number in parentheses referring to the Drug Product List is located to the right of the ingredient(s).

Additions to the Drug Product List are indicated by new information in the cumulative supplement. Additions new to the current cumulative supplement are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is dropped in subsequent cumulative supplements for that item.

Deletions from the Drug Product List are indicated by overstruck print in the cumulative supplement. Deletions new to the current cumulative supplement are indicated by the symbol >DLI> (DELETE) to the left of the line containing the overstruck print. The >DLI, symbol is dropped in subsequent cumulative supplements for that item.

A newly approved product is identified by the lozenge (☒) to the right of its strength. This identifier remains throughout all cumulative supplements for this edition.

B. ADDENDUM: DESI Pending List

Information in this cumulative supplement follows the format of the Addendum. Additions and deletions are indicated in the same manner as in the cumulative supplement to the Drug Product List. A change in Current Status of a DESI product is also indicated by an addition and a deletion.

III. SPECIAL NOTES

A. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

Categories of counts derived from product information in the Drug Product List and from this cumulative supplement are presented. The report includes counts of new molecular entities approved by the agency during the current month.

B. PRODUCTS CONTAINING PHENACETIN

The October 5, 1983, Federal Register (48FR45466) provides the following Summary: "The Food and Drug Administration (FDA) is withdrawing approval of new drug applications or parts of new drug applications that provide for drug products containing phenacetin, except for those drug products that are the subject of a hearing request. The basis of the withdrawal is phenacetin's high potential for misuse and its unfavorable benefit-to-risk ratio when incorporated in analgesic combinations which are then subject to excessive chronic use." The effective date of this withdrawal order is November 4, 1983.

Because the subject products are no longer approved, the cumulative supplement has identified them by deleting the applicable active ingredient headers followed by a reference to this Special Note.

C. THEOPHYLLINE CONTROLLED RELEASE

Two controlled released theophylline tablets are listed as therapeutically equivalent (AB). Because one of these products was recently approved for once-daily dosing, it is important to be aware that the therapeutic equivalence rating was made on the basis of 12-hour dosing intervals. The rating does not apply to once-daily dosing. To date, no data have been submitted upon which the Agency can base a therapeutic equivalence determination among any of the approved theophylline controlled-release products when dosed once-daily.

D. APPLICANT (NAME) CHANGES

Because it is not practical to identify in the cumulative supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this Special Notes section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the cumulative supplement. The current list of applicant holder changes follows.

APPLICANT (NAME) CHANGES

<u>Former Applicant (Name)</u>	<u>New Applicant (Name)</u>	<u>New Abbreviated Name</u>
STERI-MED INC SUB KETCHUM LABORATORIES INC	QUANTUM PHARMICS LTD	QUANTUM PHARMICS
KETCHUM LABORATORIES INC PROFESSIONAL PHARMACAL DIV STERI-MED INC	OPTOPICS LABORATORIES CORP	QUANTUM PHARMICS OPTOPICS LABS

The reader should consult the above cumulative list each month to become aware of such transfers and changes. By referring to the Applicant Index in the 4th Edition of the APDP, the transferred products can be identified. The reader might wish to flag these products in the List as a reminder that the applicant has been changed.

This report provides counts in several categories from the List composed of domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug and Cosmetic Act. Counts of products still pending in the DESI review are not provided. Excluded also are those approved drug products marketed by distributors; those marketed solely abroad; and products now regarded as medical devices, biologics or foods. Also not included in the counts are those items such as package size, products of a given applicant whose only distinguishing characteristics are items such as active ingredient(s), color and alternate manufacturing sites. These various counts are excluded because the Drug Product List itself excludes products from these categories.

Drug Product Count

The active moiety has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or part of a combination.

New Molecular Entity

For this report, a drug product is the representation in the Drug Product List of an active moiety (includes molecular entity and its salts, esters and derivatives) either as a single entity or as a combination product, provided in a specific dosage form and strength for a given route of administration marketed by a firm under a particular generic or trade name.

Drug Product Definition

DES1 effective and remarketed drug products which are added to the List; (2) products that are being removed from the List as the result of withdrawal, changes from prescription to over-the-counter status and discontinued marketing of products; and, (3) trends in approval of products as either a single source during each month within the quarter. The report does not reflect category changes from multistore or single source and vice versa. However, the net gain in that results from all additions, deletions and category changes is reflected in the quarterly counts for multisource and single source products.

USE OF REPORT

The following report provides summary counts derived from product information in the Drug Product List and Section B. to products in the current cumulative supplement. A new column of data will appear in Section A. each three-month period following July 1, 83. Section A. therefore will provide baseline and quarterly data while Section B. provides monthly activity.

DESCRIPTION OF REPORT

III. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

A. COUNTS CUMULATIVE BY QUARTERS

<u>CATEGORIES COUNTED</u>	<u>JULY '83 (BASELINE)</u>	<u>OCT '83</u>	<u>JAN '84</u>
DRUG PRODUCTS LISTED	6679	6783	6854
SINGLE SOURCE	1908 (28.6)	1915 (28.2%)	1933 (28.2%)
MULTISOURCE(1)	4771 (71.4)	4868 (71.8%)	4921 (71.8%)
THERAPEUTICALLY EQUIVALENT	3804 (57.0%)	3891 (57.4%)	3939 (57.5%)
NOT THERAPEUTICALLY EQUIVALENT	957 (14.3%)	967 (14.3%)	972 (14.2%)
EXCEPTIONS(2)	10 (0.1%)	10 (0.1%)	10 (0.1%)
NEW MOLECULAR ENTITIES APPROVED	-	2	8
NUMBER OF APPLICANTS	304	310	312

B. ACTIVITY FOR SUPPLEMENT NUMBER 7

	<u>FEB '84</u>	<u>MAR '84</u>	<u>CUMULATIVE</u>
DRUG PRODUCTS ADDED:			
NEWLY APPROVED	28	41	69
DESI EFFECTIVE	0	3	3
REMARKETED	0	0	0
DRUG PRODUCTS REMOVED:	7	10	17
WITHDRAWN APPROVAL	0	0	0
RX TO OTC SWITCH	0	0	0
DISCONTINUED MARKETING	9	10	19
NET GAIN IN DRUG PRODUCTS	21	31	52
SINGLE SOURCE PRODUCTS APPROVED	4	5	9
MULTISOURCE DRUG PRODUCTS APPROVED	24	36	60
NEW MOLECULAR ENTITIES APPROVED:	0	0	0
AS THE ENTITY	0	0	0
AS A SALT, ESTER OR DERIVATIVE OF THE ENTITY	0	0	0

(1) THERAPEUTIC EQUIVALENCE EVALUATIONS PROVIDED ONLY FOR MULTISOURCE PRODUCTS (I.e., AVAILABLE FROM MORE THAN ONE APPLICANT)

(2) AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE 1-5 OF THE LIST)

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN

APPROVED PRESCRIPTION DRUG PRODUCTS
DRUG PRODUCT LIST
CUMULATIVE SUPPLEMENT NUMBER 7 / AUGUST '83 - MARCH '84

ACETAMINOPHEN; CODEINE PHOSPHATE (PAGE 3-1)

CAPSULE; ORAL		
<u>ACETAMINOPHEN W/ CODEINE # 3</u>		
AA	LEMMON	<u>300MG;30MGX</u>
<u>TYLENOL W/ CODEINE NO. 3</u>		
AA	MCNEIL PHARM	<u>300MG;30MG</u>
TABLETS; ORAL		
<u>ACETAMINOPHEN AND CODEINE PHOSPHATE</u>		
AA	DURAMED PHARMS	<u>300MG;15MGX</u>
AA		<u>300MG;30MGX</u>
AA		<u>300MG;60MGX</u>
> ADD >	PAPA-DEINE # 3	
> ADD > AA	VANGARD LABS/MNM	<u>300MG;30MGX</u>
> ADD >	PAPA-DEINE # 4	
> ADD > AA	VANGARD LABS/MNM	<u>300MG;60MGX</u>

AMINO ACIDS (PAGE 3-6)

INJECTABLE; INJECTION	
<u>NEOPHAM 6.5%</u>	
CUTTER-VITRUM	<u>6.5%W</u>

ACETAMINOPHEN; HYDROCODONE BITARTRATE (PAGE 3-2)

TABLET; ORAL		
<u>HYCODAPHEN</u>		
> ADD >	BF ASCHER	<u>500MG;5MG</u>

AMINOPHYLLINE (PAGE 3-8)

/LIQUID; ORAL/		
SOLUTION; ORAL		
<u>AMINOPHYLLINE</u>		
AA	BAY LABORATORIES	<u>105MG/5MLX</u>
AA	ROXANE LABORATORIES	<u>105MG/5MLX</u>
TABLETS; ORAL		
<u>AMINOPHYLLINE</u>		
BD	BARR LABORATORIES	<u>100MGX</u>
BD		<u>200MGX</u>
AB	VANGARD LABS/MNM	<u>100MGX</u>
AB		<u>200MGX</u>

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE (PAGE 3-2)

TABLET; ORAL		
<u>CODACET</u>		
AA	HALSEY DRUG	<u>325MG;5MGX</u>
<u>/PERCOSET-5/</u>		
<u>PERCOSET</u>		

AMITRIPTYLINE HYDROCHLORIDE (PAGE 3-10)

TABLET; ORAL		
<u>AMITRIPTYLINE HCL</u>		
DANBURY PHARMACAL		
> ADD > AB		<u>10MGX</u>
> ADD > AB		<u>25MGX</u>
> ADD > AB		<u>50MGX</u>
> ADD > AB		<u>75MGX</u>
> ADD > AB		<u>100MGX</u>
> ADD > AB		<u>150MGX</u>

/ACETAMINOPHEN; PHENACETIN; PHENYLPROPANOULAMINE HYDROCHLORIDE;/
/PHENYLTOLOXAMINE CITRATE/ (PAGE 3-2)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

ALBUMIN, IODINATED, I-131, SERUM (PAGE 3-4)

INJECTABLE; INJECTION		
<u>/RADIOIODINATED SERUM ALBUMIN (HUMAN) I-HSA X-131/</u>		
<u>/MALLINCKRODT/ 16.7-250 UCI/ML/</u>		

AMPHETAMINE SULFATE (PAGE 3-13)

CAPSULE; CONTROLLED RELEASE; ORAL		
<u>/BENZEDRINE/</u>		
<u>/SK&F. LABORATORIES/ /15MG/</u>		
TABLET; ORAL		
<u>/BENZEDRINE/</u>		
<u>/SK&F. LABORATORIES/ /5MG/</u>		
<u>/10MG/</u>		

AMPICILLIN TRIHYDRATE; PROBENECID (PAGE 3-13)

POWDER FOR RECONSTITUTION; ORAL		
<u>POLYCILLIN-PRB</u>		
AB	BRISTOL LABS/B-M	<u>EQ 3.5GM BASE/BOT;15M/BOT</u>
<u>PROBAMPACIN</u>		
AB	BIOCRAFT LABS	<u>EQ 3.5GM BASE/BOT;15M/BOT</u>

ASPIRIN; BUTALBITAL; CAFFEINE (PAGE 3-15)	TABLET; ORAL	AZOTAL ADRIA LABORATORIES 650MG;50MG	ASPIRIN AND CAFFEINE M/ BUTALBITAL ASPIRIN 325MG;50MG;40MG PURPAC/KALIPIHARMA 325MG;50MG;40MG BUTALBITAL M/ ASPIRIN AND CAFFEINE CHELSEA LABORATORIES 325MG;50MG;40MGx > ADD > AB BUTALBITAL M/ ASPIRIN & CAFFEINE BOOTS LABORATORIES 325MG;50MG;40MGx ASPIRIN; BUTALBITAL; CAFFEINE (PAGE 3-15)
ASPIRIN; HYDROCODEINE BITARTATE (PAGE 3-15)	TABLET; ORAL	ASPIRIN AND CAFFEINE M/ BUTALBITAL ASPIRIN 325MG;50MG;40MG PURPAC/KALIPIHARMA 325MG;50MG;40MG BUTALBITAL M/ ASPIRIN AND CAFFEINE CHELSEA LABORATORIES 325MG;50MG;40MGx > ADD > AB BUTALBITAL M/ ASPIRIN & CAFFEINE BOOTS LABORATORIES 325MG;50MG;40MGx ASPIRIN; HYDROCODEINE BITARTATE (PAGE 3-15)	ASPIRIN; HYDROCODEINE BITARTATE (PAGE 3-15)
ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE (PAGE 3-17)	LIQUID; ORAL	/LIQUIDATE/ /LUDOXATE/ /66/ /COPD; LABORATORY/ /6.425MG/ML; 2.5MG/ML/ /2.5MG/ML / /LUDOXATE/ /LIQUID/ (PAGE 3-18)	CAPSULE; ORAL ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE (PAGE 3-17)
(ALL PRODUCTS - SEE SPECIAL NOTE B.)		/ASPIRIN; CAFEINE; BUTALBITAL; DIPHENOXYLATE HYDROCHLORIDE/ (PAGE 3-15)	ASPIRIN; CAFEINE; DIPHENOXYLATE HYDROCHLORIDE (PAGE 3-16)
(ALL PRODUCTS - SEE SPECIAL NOTE B.)		/ASPIRIN; CAFEINE; BUTALBITAL; DIPHENOXYLATE HYDROCHLORIDE/ (PAGE 3-15)	ASPIRIN; CAFEINE; PROPOXYPHENE HYDROCHLORIDE (PAGE 3-16)
(ALL PRODUCTS - SEE SPECIAL NOTE B.)		/ASPIRIN; CAFEINE; BUTALBITAL; DIPHENOXYLATE HYDROCHLORIDE/ (PAGE 3-15)	ASPIRIN; CARISOPRODOL (PAGE 3-16)
ASPIRIN; CARISOPRODOL (PAGE 3-16)	CAPSULE; ORAL	DARVON COMPOUND-65 DARVON COMPOUND-65 PIZZER LABS/PFIZER 800MG CAPSULE; ORAL BACAMPICILLIN HYDROCHLORIDE (PAGE 3-18)	ASPIRIN; CARISOPRODOL (PAGE 3-16)
ASPIRIN; CARISOPRODOL (PAGE 3-16)	CAPSULE; ORAL	LEMON PROPOXYPHENONE COMPOUND 65 SK-65 COMPOUND SK-65 LABORATORIES 389MG;32.4MG;65MGx ASPIRIN; CARISOPRODOL (PAGE 3-16)	ASPIRIN; CARISOPRODOL (PAGE 3-16)
ASPIRIN; CARISOPRODOL (PAGE 3-16)	SOLID	CHYMEX SOLUTION; ORAL BENTROMIDE (PAGE 3-19)	ASPIRIN; CARISOPRODOL (PAGE 3-16)
ASPIRIN; CARISOPRODOL (PAGE 3-16)	SOLID	ADRIA LABORATORIES 500MG;7.5MLx SOMA COMPOUND WALLACE PHARMS/C-W 325MG;200MGx	ASPIRIN; CARISOPRODOL (PAGE 3-16)

BENZTHIAZIDE (PAGE 3-20)

TABLET; ORAL

AQUATAG

> DLT > /BP/ /CORP. LABORATORIES/ /50MG/
> DLT > /BP/ /25MG/
> ADD > BP REID-PROVIDENT LABS 50MG
> ADD > 25MG
/PROQUA/
/BP/ /REID-PROVIDENT LABS//50MG/

BENZTROPINE MESYLATE (PAGE 3-20)

TABLET; ORAL

BENZTROPINE MESYLATE

BP	QUANTUM PHARMICS	0.5MGX
BP		1MGX
BP		2MGX
BP	COGENTIN	
BP	MS&D/MERCK	0.5MG
BP		1MG
BP		2MG

BETAMETHASONE VALERATE (PAGE 3-21)

CREAM; TOPICAL

BETAMETHASONE VALERATE

AB	E FOUGERA/BYK-GLDN	EQ 0.1% BASEN
AB	PHARMADERM/BYK-GLDN	EQ 0.1% BASEN
AB	BETATREX	
AB	SAVAGE LABS/BYK-GLDN	EQ 0.1% BASEN

LOTION; TOPICAL

BETAMETHASONE VALERATE

AB	E FOUGERA/BYK-GLDN	EQ 0.1% BASEN
AB	PHARMADERM/BYK-GLDN	EQ 0.1% BASEN

BETATREX

AB	SAVAGE LABS/BYK-GLDN	EQ 0.1% BASEN
----	----------------------	---------------

VALTSONE

AB	SCHERING	EQ 0.1% BASE
----	----------	--------------

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

AB	E FOUGERA/BYK-GLDN	EQ 0.1% BASEN
AB	PHARMADERM/BYK-GLDN	EQ 0.1% BASEN

BETATREX

AB	SAVAGE LABS/BYK-GLDN	EQ 0.1% BASEN
----	----------------------	---------------

VALTSONE

AB	SCHERING	EQ 0.1% BASE
----	----------	--------------

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE (PAGE 3-22)

SYRUP; ORAL

AMBENYL

MARION LABORATORIES 12.5MG/5ML;10MG/5ML

BROMPHENIRAMINE MALEATE (PAGE 3-22)

TABLET; ORAL

BROMPHENIRAMINE MALEATE

/AA/ /POLAR PHARMACEUTICAL/ 4MG/

> ADD > BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE;
> ADD > PHENYLPROPANOLAMINE HYDROCHLORIDE (PAGE 3-23)

> ADD > SYRUP; ORAL
> ADD > DIMETANE-DC
> ADD > AH ROBINS 2MG/5ML;10MG/5ML;12.5MG/5ML

> ADD > BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE;
> ADD > PSEUDOEPHEDRINE HYDROCHLORIDE (PAGE 3-23)

> ADD > SYRUP; ORAL
> ADD > DIMETANE-DX
> ADD > AH ROBINS 2MG/5ML;10MG/5ML;30MG/5ML

> ADD > BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE (PAGE 3-23)

> ADD > ELIXIR; ORAL
> ADD > ELIXIR DIMETAPP
> ADD > AH ROBINS 4MG/5ML;25MG/5ML

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE (PAGE 3-23)

INJECTABLE; INJECTION

MARCATHINE HCL W/ EPINEPHRINE

AP	BREON LABS/STERLING	0.5%;0.0091MG/ML
AP		0.75%;0.0091MG/ML

AP	SENSORCATHINE	
AP	ASTRA HOSP PHARM	0.5%;0.0091MG/ML
AP		0.75%;0.0091MG/ML

CAPSULE: ORAL
BUTAERIBITAL SODIUM (PAGE 3-24)
CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM
ACETATE; SODIUM CHLORIDE (PAGE 3-26)
SOLUTIION: INTRADERMAL

DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 7 / AUGUST '83 - MARCH '84

4

4

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN

CEPHALOTHIN SODIUM (PAGE 3-31)

INJECTABLE; INJECTION

SEFFIN

<u>AP</u>	<u>GLAXO</u>	<u>EQ 1GM BASE/VIAL*</u>
<u>AP</u>		<u>EQ 2GM BASE/VIAL*</u>
		<u>EQ 10GM BASE/VIAL*</u>

CEPHALOTHIN SODIUM; DEXTROSE (PAGE 3-31)

INJECTABLE; INJECTION

CEPHALOTHIN SODIUM IN PLASTIC CONTAINER

TRAIVENOL LABS	EQ 20MG BASE/ML;50MG/ML*
	EQ 40MG BASE/ML;50MG/ML*

CEPHALOTHIN SODIUM; SODIUM CHLORIDE (PAGE 3-31)

INJECTABLE; INJECTION

CEPHALOTHIN SODIUM IN PLASTIC CONTAINER

TRAIVENOL LABS	EQ 20MG BASE/ML;9MG/ML*
	EQ 40MG BASE/ML;9MG/ML*

CHLORDIAZEPOXIDE (PAGE 3-33)

CAPSULE, CONTROLLED RELEASE; ORAL

LIBRELEASE

HOFFMANN-LA ROCHE	30MG*/
-------------------	--------

CHLORDIAZEPOXIDE HYDROCHLORIDE (PAGE 3-33)

CAPSULE; ORAL

CHLORDIAZEPOXIDE HCL

/AB/	/BOOTS PHARMACEUTICAL/	5MG/
/AB/		10MG/
/AB/		25MG/

CHLOROPROCaine HYDROCHLORIDE (PAGE 3-34)

INJECTABLE; INJECTION

NESACaine

/PENNWALT PHARM/	/1/
	/2/

ASTRA PHARM PRODS	1%
	2%

/AB/	/PENNWALT PHARM/	/2/
/AB/		/3/
AP	ASTRA PHARM PRODS	2%
AP		3%

CHLORTHIAZIDE (PAGE 3-35)

TABLET; ORAL

CHLORTHIAZIDE

<u>AB</u>	<u>CHELSEA LABORATORIES</u>	<u>250MG*</u>
<u>AB</u>		<u>500MG*</u>

CHLORTHIAZIDE; RESERPINE (PAGE 3-35)

TABLET; ORAL

CHLORTHIAZIDE AND RESERPINE

BP	WEST-WARD	250MG;0.125MG*
BP		500MG;0.125MG*

CHLORPHENIRAMINE MALEATE (PAGE 3-36)

TABLET; ORAL

CHLORPHENIRAMINE MALEATE

/AA/	/TOWNE PAULSEN/	/4MG/
------	-----------------	-------

CHLORPROPAMIDE (PAGE 3-38)

TABLET; ORAL

CHLORPROPAMIDE

<u>AB</u>	<u>PAR PHARMACEUTICAL</u>	<u>100MG*</u>
<u>AB</u>		<u>250MG*</u>
AB	DIABINESE	
AB	PFIZER LABS/PFIZER	100MG

CHLORTHALIDONE (PAGE 3-38)

TABLET; ORAL

CHLORTHALIDONE

AB	PUREPAC/KALIPHARMA	50MG*
----	--------------------	-------

CHLORZOXAZONE (PAGE 3-39)

TABLET; ORAL

CHLORZOXAZONE

AA	PAR PHARMACEUTICAL	250MG*
----	--------------------	--------

CHYMOPAPAIN (PAGE 3-39)

INJECTABLE; INJECTION

DISCASE

TRAIVENOL LABS	12,500 UNITS/VIAL*
----------------	--------------------

DEXCHLORPHENIRAMINE MALEATE (PAGE 3-51)

SYRUP; ORAL
 > ADD > AA BAYLARAMINE
 > ADD > AA BAY LABORATORIES 2MG/5MLX
 > ADD > AA POLARAMINE
 > ADD > AA SCHERING 2MG/5ML

DEXTROSE; DOPAMINE HYDROCHLORIDE (PAGE 3-53)

INJECTABLE; INJECTION
 /DOPAMINE HCL IN DEXTROSE 5%/
DOPAMINE HCL
 AP ABBOTT LABORATORIES 5GM/100ML;80MG/100ML
 AP 5GM/100ML;160MG/100ML
 AP DOPAMINE HCL IN PLASTIC CONTAINER
 AP ABBOTT LABORATORIES 5GM/100ML;80MG/100ML
 AP 5GM/100ML;160MG/100ML
 AP 5GM/100ML;320MG/100MLX

DEXTROSE; HEPARIN SODIUM (PAGE 3-53)

INJECTABLE; INJECTION
 HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER
 TRAVENOL LABS 5GM/100ML;4,000 UNITS/100MLX

DEXTROSE; LIDOCAINE HYDROCHLORIDE (PAGE 3-53)

INJECTABLE; INJECTION
LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER
 > ADD > AP AM MCGAW/AM HOSP 5GM/100ML;200MG/100MLX
LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
 > ADD > AP AM MCGAW/AM HOSP 5GM/100ML;400MG/100MLX
LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER
 > ADD > AP AM MCGAW/AM HOSP 5GM/100ML;800MG/100MLX

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM (PAGE 3-57)

INJECTABLE; INJECTION
 /DIATRIZOATE 'MEGLUMINE' AND DIATRIZOATE 'SODIUM'/
DIATRIZOATE-60

DIETHYLPROPION HYDROCHLORIDE (PAGE 3-59)

TABLET; ORAL
 AA DIETHYLPROPION HCL
 CAMALL 25MGX

DIMENHYDRINATE (PAGE 3-60)

INJECTABLE; INJECTION
DIMENHYDRINATE
 /AP/ /INT'L MEDICATION SYS//50MG/ML/

DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-61)

CAPSULE; ORAL
SK-DIPHENHYDRAMINE
 /AA/ SK&F LABORATORIES /15MG/

 ELIXIR; ORAL
BELIX
 AA HALSEY DRUG 12.5MG/5MLX
DIBENTIL
 AA HR CENCI LABS 12.5MG/5MLX
 /AA/ CORD LABORATORIES/ /12.5MG/5ML/
 /AA/ /SK-DIPHENHYDRAMINE/
 /AA/ /SK&F LABORATORIES/ /12.5MG/5ML/

DISULFIRAM (PAGE 3-63)

TABLET; ORAL
DISULFIRAM
 BX CHELSEA LABORATORIES 250MGX
 BX 500MGX
 BX SIDMAK LABORATORIES 250MGX
 BX 500MGX

DOXYCYCLINE HYCLATE (PAGE 3-64)

CAPSULE; ORAL
DOXYCYCLINE HYCLATE
 AB CHELSEA LABORATORIES EQ 50MG BASE
 AB HEATHER DRUG EQ 50MG BASEX
 AB EQ 100MG BASEX
 AB PAR PHARMACEUTICAL EQ 100MG BASEX
 AB PUREPAC/KALIPHARMA EQ 50MG BASEX
 AB EQ 100MG BASEX

 INJECTABLE; INJECTION
DOXY 100
 AP LYPO-MED EQ 100MG BASE/VIALX
DOXY 200
 AP LYPO-MED EQ 200MG BASE/VIALX
DOXYCYCLINE
 AP ELKINS-SINN EQ 100MG BASE/VIALX
 AP EQ 200MG BASE/VIALX
VIBRAMYCIN
 AP PFIZER LABS/PFIZER EQ 200MG BASE/VIAL

ERGOLOID MESYLATES (PAGE 3-66)

44 - MARCII - 83 / AUGUST - 83 / CUMULATIVE SUPPLEMENT NUMBER 7 / RUE DE PRODUCE LIST / CUMULATIVE

HEATHER DRUGS
DIASTROPHIC METACARPIA
CHELSEA METABOLITES
ERGOSOLID METABOLITES
E2 100MG BASE

EROTEROPEPTIDOL; ERYTHROMYCIN (PAGE 3-64) EENTANYL CITRATE (PAGE 3-66)

CYCLOLONINE HYDROCHLORIDE (PAGE 3-64)

ECHOGRAPHIC JOIDEE (PAGE 3-65)

POWDER FOR RECONSTITUTION; OPTHALMIC VEPESI

ENTANAL CIRRATE (PAGE 3-75)

AYERST LABS/AMHO 0.03% SUBLIMAZE

FLUOCINOLONE ACETONIDE (PAGE 2 OF 2)

CAPSULE; ORAL HYDROGENE/LC	AT	SOLUTIION; TOPICAL FLUOCINOLONE ACETONIDE	0.0125mg
ERGOLOID MESYLATES (PAGE 3-66)	AT	OINTMENT; TOPICAL FLUOCINOLONE ACETONIDE	0.025mg
ERGOLOID MESYLATES (PAGE 3-66)	AT	PHARMAFAIR FLUOCINOLONE ACETONIDE	0.025mg
PHARMATON/SZ	AT	NMC LABORATORIES FLUOCET	0.0125mg
LIDOCARION	AT	CREAM; TOPICAL FLUOCET	0.025mg

DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 7 / AUGUST '83 - MARCH '84

9

FLUOXYMESTERONE (PAGE 3-77)

TABLET; ORAL
FLUOXYMESTERONE
 BP BOLAR PHARMACEUTICAL 2MGx
 BP 5MGx
 BP 10MGx
 BP COLMED LABORATORIES 10MGx

FOLIC ACID (PAGE 3-78)

TABLET; ORAL
FOLIC ACID

> ADD > AA VANGARD LABS/MNM 1MGx

FUROSEMIDE (PAGE 3-79)

INJECTABLE; INJECTION

FUROSEMIDE
 AP NATCON CHEMICAL 10MG/MLx
 TABLET; ORAL
FUROSEMIDE
 AB BARR LABORATORIES 60MGx
 AB INT'L MEDICATION SYS 20MGx
 AB 60MGx
 AB ROXANE LABORATORIES 20MGx
 AB 60MGx
 AB ZENITH LABORATORIES 20MGx
 AB 60MGx

GENTAMICIN SULFATE (PAGE 3-79)

CREAM; TOPICAL
GENTAFAIR
 AT PHARMAFAIR EQ 1MG BASE/GMx
 AT GENTAMICIN SULFATE
 AT NMC LABORATORIES EQ 1MG BASE/GMx

INJECTABLE; INJECTION

GENTAMICIN SULFATE
 AP ABBOTT LABORATORIES EQ 60MG BASE/100MLx
 AP EQ 70MG BASE/100MLx
 AP EQ 80MG BASE/100MLx
 AP EQ 90MG BASE/100MLx
 AP EQ 100MG BASE/100MLx
 AP EQ 1.2MG BASE/MLx
 AP EQ 1.4MG BASE/MLx
 AP EQ 1.6MG BASE/MLx
 AP EQ 1.8MG BASE/MLx
 AP EQ 2MG BASE/MLx
 AP LYPHO-MED

GENTAMICIN SULFATE (PAGE 3-79)

INJECTABLE; INJECTION

GENTAMICIN SULFATE IN PLASTIC CONTAINER
 AP ABBOTT LABORATORIES EQ 60MG BASE/100MLx
 AP EQ 70MG BASE/100MLx
 AP EQ 80MG BASE/100MLx
 AP EQ 90MG BASE/100MLx
 AP EQ 100MG BASE/100MLx
 AP EQ 1.2MG BASE/MLx
 AP EQ 1.4MG BASE/MLx
 AP EQ 1.6MG BASE/MLx
 AP EQ 1.8MG BASE/MLx
 AP EQ 2MG BASE/MLx

OINTMENT; TOPICAL

GENTAMICIN SULFATE
 > ADD > AT NMC LABORATORIES EQ 1MG BASE/GMx
 AT THAMES PHARMACAL EQ 1MG BASE/GMx

SOLUTION/DROPS; OPHTHALMIC

> ADD > AT COOPERVISION PHARMS EQ 3MG BASE/MLx

GONADOTROPIN, CHORIONIC (PAGE 3-81)

INJECTABLE; INJECTION
 /ANTUITRIN'S/
 /AP/ /PARKE-DAVIS/N-L/ /5,000 UNITS/VIAL/

GRISEOFULVIN, ULTRAMICROCRYSTALLINE (PAGE 3-82)

TABLET; ORAL

FULVICIN P/G 165
 AB SCHERING 165MG
 AB FULVICIN P/G 330
 AB SCHERING 330MG
 AB GRISACTIN ULTRA
 AB AYERST LABS/AMHO 165MGx
 AB 330MGx

HEPARIN SODIUM (PAGE 3-83)

INJECTABLE; INJECTION
HEPARIN SODIUM
 AP NATCON CHEMICAL 1,000 UNITS/MLx

HEPARIN SODIUM; SODIUM CHLORIDE - IN PLASTIC (PAGE 3-85)

INJECTABLE; INJECTION
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%
 AP ABBOTT LABORATORIES 10,000 UNITS/100ML; 450MG/100MLx

HYDROCORTISONE ACETATE (PAGE 3-93)

LOTION; TOPICAL

/HYDROCORTISONE ACETATE/

/AB/ /TOHNE PAULSEN/ /0.5%/

/SUSPENSION/ DROPS; OPHTHALMIC; Otic/

/HYDROCORTISONE/

/MSD/MERCK/ /2.5%/

HYDROCORTISONE VALERATE (PAGE 3-95)

OINTMENT; TOPICAL

WESTCORT

WESTWOOD PHARMS 0.2%

HYDROFLUMETHIAZIDE; RESERPINE (PAGE 3-95)

TABLET; ORAL

HYDROFLUMETHIAZIDE AND RESERPINE

BP COLMED LABORATORIES 50MG;0.125MG

HYDROMORPHONE HYDROCHLORIDE (PAGE 3-95)

INJECTABLE; INJECTION

DILAUDID-HP

KNOLL PHARMACEUTICAL 10MG/ML

HYDROXYZINE HYDROCHLORIDE (PAGE 3-96)

TABLET; ORAL

HYDROXYZINE HCL

AB BARR LABORATORIES 10MG

AB DANBURY PHARMACAL 10MG

AB 25MG

AB 50MG

HYDROXYZINE PAMOATE (PAGE 3-96)

CAPSULE; ORAL

HYDROXYZINE PAMOATE

AB DURAMED PHARMS EQ 25MG HCL

AB EQ 50MG HCL

AB EQ 100MG HCL

AB EQ 25MG HCL

AB EQ 50MG HCL

IBUPROFEN (PAGE 3-97)

TABLET; ORAL

MOTRIN

> ADD > AB UPJOHN MANUFACTURING 600MG

RUFEN

> ADD > AB BOOTS PHARMACEUTICAL 600MG

IMIPRAMINE HYDROCHLORIDE (PAGE 3-97)

TABLET; ORAL

ANTIPRESS

/BB/ /LEMON/ /25MG/

/AB/ /IMAVATE/ /25MG/

/AB/ /AH ROBINS/ /50MG/

IMIPRAMINE HCL

AB PAR PHARMACEUTICAL 10MG

AB 25MG

AB 50MG

ISOETHARINE HYDROCHLORIDE (PAGE 3-100)

SOLUTION; INHALATION

ISOETHARINE HCL

> ADD > AN ARMOUR PHARM 0.167%

> ADD > AN 0.2%

> ADD > AN 0.25%

AN INT'L MEDICATION SYS 0.167%

AN ROXANE LABORATORIES 0.167%

> ADD > AN TRAVENOL LABS 0.14%

AN 0.25%

ISONIAZID (PAGE 3-101)

SYRUP; ORAL

ISONIAZID

AA CAROLINA MED PRODS 50MG/5ML

RIMIFON

AA HOFFMANN-LA ROCHE 50MG/5ML

ISOPROTERENOL HYDROCHLORIDE (PAGE 3-102)

SOLUTION; INHALATION

ISOPROTERENOL HCL

/AN/ /INT'L MEDICATION SYS/ 0.5%

DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 7 / AUGUST '83 - MARCH '84

13

NITROGLYCERIN (PAGE 3-128)

INJECTABLE; INJECTION

NITRONAL

AP G POHL-BOSKAMP 5MG/MLX
1MG/MLX

TRIDIL

AM CRITICAL CARE/AHS 0.5MG/MLX

NYSTATIN (PAGE 3-129)

OINTMENT; TOPICAL

NYSTATIN

AT CLAY-PARK LABS 100,000 UNITS/GMX

POWDER; ORAL

NILSTAT

LEDERLE LABS/AM CYAN 100%MX

NYSTATIN (PAGE 3-129)

TABLET; ORAL

NYSTATIN

AA PAR PHARMACEUTICAL 500,000 UNITSMX

TABLET; VAGINAL

NYSTATIN

AT E FOUGERA/BYK-GLDN 100,000 UNITSMX
AT PHARMADERM/BYK-GLDN 100,000 UNITSMX

OXPRENOLOL HYDROCHLORIDE (PAGE 3-131)

CAPSULE; ORAL

TRASICOR

CIBA/CIBA-GEIGY 20MGX
40MGX
80MGX
160MGX

OXTRIPTYLLINE (PAGE 3-131)

ELIXIR; ORAL

OXTRIPTYLLINE

BAY LABORATORIES 100MG/5MLX

OXTRIPTYLLINE (PAGE 3-131)

SYRUP; ORAL

CHOLEDYL

AA PARKE-DAVIS/W-L 50MG/5ML

OXTRIPTYLLINE PEDIATRIC

AA BAY LABORATORIES 50MG/5MLX

TABLET, ENTERIC COATED; ORAL

CHOLEDYL

AB PARKE-DAVIS/W-L 100MG

200MG

OXTRIPTYLLINE

AB BOLAR PHARMACEUTICAL 100MGMX

200MGMX

OXYTETRACYCLINE HYDROCHLORIDE (PAGE 3-132)

CAPSULE; ORAL

/OXLOPAR/

/AB/ /PARKE-DAVIS/W-L/ /EG '250MG 'BASE/

PENICILLIN V POTASSIUM (PAGE 3-135)

POWDER FOR RECONSTITUTION; ORAL

/UTICILLIN 'VK/

/AA/ /UP JOHN/ /EG '125MG 'BASE/5ML/

/AA/ /EG '250MG 'BASE/5ML/

PHENDIMETRAZINE TARTRATE (PAGE 3-138)

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

AA FERNDALE LABS 35MGX

PHENTERMINE HYDROCHLORIDE (PAGE 3-139)

CAPSULE; ORAL

ADIPEX-P

AA LEMMON 37.5MGX

DAPEX-37.5

AA FERNDALE LABS 37.5MGX

PHENTERMINE HCL

AA CAMALL 37.5MGX

POTASSIUM CHLORIDE (PAGE 3-143)

PREDNISOLONE TEBUTATE (PAGE 3-147)

INJECTABLE; INJECTION

HYDROTRA-TBA

BP MSD/MERCK 20MG/ML

PREDNISOLONE TEBUTATE

BP CARTER-GLOGAU LABS 20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

POTASSIUM CHLORIDE

/AP/ /MFG/ML/

INJECTABLE; INJECTION

BP

PREDNISOLONE TEBUTATE

BP

CARTER-GLOGAU LABS

20MG/ML

TRAVENOL LABS

/AP/ /MFG/ML/

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
(PAGE 3-155)

SYRUP; ORAL
ACTAHIST
AA HR CENCI LABS 30MG/5ML; 1.25MG/5MLX
/PSEUDODINE/
/AA/ BAY LABORATORIES /30MG/5ML; 1.25MG/5ML/
/AA/ TRIACIN /NATL PHARM MFG/BARRE/30MG/5ML; 1.25MG/5ML/
TRIPOSED
AA HALSEY DRUG 30MG/5ML; 1.25MG/5MLX

TABLET; ORAL
/TRI-SUD/
/AA/ MD PHARMACEUTICAL /60MG; 2.5MG/
/TRIPOURINE/
/AA/ PANBURY PHARMACEUTICAL /60MG; 2.5MG/
TRIPROLIDINE AND PSEUDOEPHEDRINE
AA BOLAR PHARMACEUTICAL 60MG; 2.5MGX
/AA/ WEST-WARD /60MG; 2.5MG/
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL
AA CHELSEA LABORATORIES 60MG; 2.5MGX

QUINIDINE GLUCONATE (PAGE 3-157)

TABLET, CONTROLLED RELEASE; ORAL
QUINIDINE GLUCONATE
AB ROXANE LABORATORIES 324MGX

QUINIDINE SULFATE (PAGE 3-157)

TABLET; ORAL
QUINIDINE SULFATE
AB VITARINE/WEST CHEM 300MGX

RESERPINE (PAGE 3-158)

TABLET; ORAL
/RAURINE/
/BP/ /ONEAL, JONES/FELDMAN//0.25MG/
RESERPINE
/BP/ /CORD. LABORATORIES/ /0.1MG/
/BP/ /0.25MG/
> DLT > /BP/ MYLAN PHARMS /0.1MG/
> DLT > /BP/ /0.25MG/

RESERPINE (PAGE 3-158)

TABLET; ORAL
/VIO-SERPINE/
/BP/ /ROWELL LABORATORIES//0.1MG/
/BP/ /0.25MG/

SECOBARBITAL SODIUM (PAGE 3-160)

CAPSULE; ORAL
SECOBARBITAL SODIUM
AA LANNETT 50MG
SECONAL SODIUM
AA ELI LILLY 50MGX
AA 100MGX

SELENIUM SULFIDE (PAGE 3-161)

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE
AT BAY LABORATORIES 2.5%

SILVER SULFADIAZINE (PAGE 3-161)

CREAM; TOPICAL
SILVER SULFADIAZINE/
SSD

SITOOSTEROL; ALPHA (PAGE 3-161)

/SUSPENSION; ORAL/
/CYTELLIN/
/ELI LILLY/ /360/15ML/

SODIUM CHLORIDE (PAGE 3-162)

INJECTABLE; INJECTION
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER
TRAIVENOL LABS 3GM/100MLX
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER
TRAIVENOL LABS 5GM/100MLX

SODIUM POLYSTYRENE SULFONATE (PAGE 3-165)

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
AA ROXANE LABORATORIES 15GM/60MLX
SPS
AA CAROLINA MED PRODS 15GM/60ML

SOMATROPIN (PAGE 3-165)

INJECTABLE; INJECTION
ASELLACRIN 2
SERONO LABS 2 IU/VIALX
/ASELLACRIN/
ASELLACRIN 10

THIORIDAZINE HYDROCHLORIDE (PAGE 3-178)

CONCENTRATE; ORAL

THIORIDAZINE HCL

<u>AA</u>	CORD LABORATORIES	<u>30MG/MLX</u>
<u>AA</u>		<u>100MG/MLX</u>
<u>AA</u>	NATL PHARM MFG/BARRE	<u>100MG/MLX</u>

TABLET; ORAL

MELLARIL

<u>AB</u>	SANDOZ PHARMS/SANDOZ	<u>100MG</u>
<u>> ADD > AB</u>		<u>150MG</u>
<u>> ADD > AB</u>		<u>200MG</u>

THIORIDAZINE HCL

<u>AB</u>	BARR LABORATORIES	<u>10MGX</u>
<u>AB</u>		<u>15MGX</u>
<u>AB</u>		<u>25MGX</u>
<u>AB</u>		<u>50MGX</u>
<u>AB</u>		<u>100MGX</u>
<u>AB</u>	BOLAR PHARMACEUTICAL	<u>10MGX</u>
<u>AB</u>		<u>100MGX</u>
<u>AB</u>		<u>100MGX</u>
<u>> ADD > AB</u>		<u>150MGX</u>
<u>> ADD > AB</u>		<u>200MGX</u>
<u>AB</u>	CORD LABORATORIES	<u>10MGX</u>
<u>AB</u>		<u>15MGX</u>
<u>AB</u>		<u>25MGX</u>
<u>AB</u>		<u>50MGX</u>
<u>AB</u>	DANBURY PHARMACAL	<u>10MGX</u>
<u>AB</u>		<u>15MGX</u>
<u>AB</u>		<u>25MGX</u>
<u>AB</u>		<u>50MGX</u>
<u>AB</u>	MYLAN PHARMS	<u>100MGX</u>
<u>AB</u>	PAR PHARMACEUTICAL	<u>10MGX</u>
<u>AB</u>		<u>15MGX</u>
<u>AB</u>		<u>25MGX</u>
<u>AB</u>		<u>50MGX</u>
<u>AB</u>		<u>100MGX</u>
<u>> ADD > AB</u>	ROXANE LABORATORIES	<u>10MGX</u>
<u>> ADD > AB</u>		<u>25MGX</u>
<u>> ADD > AB</u>		<u>50MGX</u>
<u>> ADD > AB</u>	WEST-WARD	<u>10MGX</u>
<u>> ADD > AB</u>		<u>15MGX</u>
<u>> ADD > AB</u>		<u>25MGX</u>
<u>> ADD > AB</u>	ZENITH LABORATORIES	<u>50MGX</u>
<u>AB</u>		<u>100MGX</u>

TIMOLOL MALEATE (PAGE 3-179)

TABLET; ORAL

BLOCADREN
MS&D/MERCK

5MG

TRIAMCINOLONE (PAGE 3-180)

TABLET; ORAL

TRIAMCINOLONE

<u>> DLT > /BP/</u>	MYLAN PHARMS	<u>/4MG/</u>
<u>> DLT > /BP/</u>		<u>/8MG/</u>

TRIAMCINOLONE ACETONIDE (PAGE 3-180)

AEROSOL; INHALATION

/ARISTOCORT//LEPERLE LABS/AM CYAN/0.25MG/INH/

AZMACORT

WILLIAM H RORER 0.25MG/INH

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDEBAY LABORATORIES 0.025%W0.1%W0.5%WATTRIDERMDEL-RAY LABORATORIES 0.1%WAT

TROPICAMIDE (PAGE 3-166)
/AB/ /ZENITH LABORATORIES/ /
/AB/ /TRITONE SILICA/ 2/
/AB/ /ELDER PHARMACEUTICALS/
/AB/ /GUADETTES/
TALLET ORAL

ROFLCATS (PAGE 3-188)

/QUADERTS/ /ELDER PHARMS/ /TRIPLE SILFAZ/ /AB/ /600ML

TABLET; ORAL

TRISULFAPYRIMIDINES (PAGE 3-185)

N 1 2010

Original from
UNIVERSITY OF MICHIGAN

DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 7 / AUGUST '83 - MARCH '84

Digitized by Google

91

ADDENDUM
DESI PENDING LIST - 'EXEMPT' (COURT ORDER) CATEGORY
CUMULATIVE SUPPLEMENT NUMBER 6 / AUGUST '83 - FEBRUARY '84

> DLT > /AMINOPHYLLINE PHENOBARBITAL'S RACEPHEDRINE HYDROCHLORIDE/
(PAGE AD2)

> DLT > /TABLET; ORAL/
> DLT > /AMODRINE/
> DLT > /SEARLE PHARMS/ /100MG;30MG;25MG/

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL;
ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE
HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE
HYDROCHLORIDE; VITAMIN A; VITAMIN E (PAGE AD2)

INJECTABLE; INJECTION

MVC PLUS
ASCOT HOSP PHARMS 10MG/ML;0.006MG/ML;0.5 UGM/ML;
1.5MG/ML;20 IU/ML;0.04MG/ML;
4MG/ML;0.4MG/ML;0.36MG/ML;
0.3MG/ML;330 IU/ML;1 IU/ML

DIPYRIDAMOLE (PAGE AD4)

TABLET; ORAL	
DIPYRIDAMOLE	
ASCOT HOSP PHARMS	50MG
DURAMED PHARMS	25MG
	50MG
	75MG
HALSEY DRUG	50MG
SUPERPHARM	50MG

ISOSORBIDE DINITRATE (PAGE AD5)

TABLET; ORAL	
ISOSORBIDE DINITRATE	
BARR LABORATORIES	30MG

/METHANDROSTÉNOLONE (PAGE AD6)

/TABLET; ORAL/
/METHANDROSTÉNOLONE/
/PAR PHARMACEUTICAL/ /2.5MG/
/5MG/

/BROMPHÉNTRAMINE MALEATES PHÉNylephrine HYDROCHLORIDE/
/PHENYLPROPANOLAMINE HYDROCHLORIDE/ (PAGE AD3)

/ELIXIR; ORAL/
/ELIXIR; DIMEТАПР/
/AH ROBINS/ /4MG/5ML;5MG/5ML;5MG/5ML/

/TABLET; CONTROLLED RELEASE; ORAL/
/DIMEТАПР/
/AH ROBINS/ /12MG;15MG;15MG/

/CARAMIPHEN ÉUSSYLATE; CHLORPHÉNTRAMINE MALEATES ISOPROPAMIDE/
/IODIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE/ (PAGE AD3)

/CAPSULE; CONTROLLED RELEASE; ORAL/
/TUSS-ORNADE/
/SK&F. LABORATORIES/ /20MG;30MG;2.5MG;50MG/

/SOLUTION; ORAL/
/TUSS-ORNADE/
/SK&F. LABORATORIES/ /5MG/5ML;2MG/5ML;0.75/5ML;15MG/5ML/

DICYCLOMINE HYDROCHLORIDE (PAGE AD3)

SYRUP; ORAL
BAYCYCLOMINE
BAY LABORATORIES 10MG/5ML

